CFA + rFSH
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Infertility, Female
Conditions
Infertility, Female, Endometrial Diseases
Trial Timeline
Jan 29, 2020 → May 22, 2023
NCT ID
NCT03755973About CFA + rFSH
CFA + rFSH is a approved stage product being developed by Merck for Infertility, Female. The current trial status is completed. This product is registered under clinical trial identifier NCT03755973. Target conditions include Infertility, Female, Endometrial Diseases.
What happened to similar drugs?
15 of 20 similar drugs in Infertility, Female were approved
Approved (15) Terminated (4) Active (5)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03755973 | Approved | Completed |
Competing Products
20 competing products in Infertility, Female